STE is the ticker symbol for STERIS plc, a publicly traded Healthcare sector company listed on NYSE. 13F Pro tracks STE with AI-powered analysis, an AI quality score, SEC EDGAR financials, insider transactions, and institutional 13F holdings — all sourced directly from public SEC filings.

Is STE a good stock to buy?

13F Pro's AI ranking engine scores STE at 68.0/100, ranked #328 of 2,925 stocks on a composite quality score built from its SEC filings, covering profitability, growth, balance sheet strength, and free cash flow. The full AI verdict and bull/bear case for STE is available at https://13fpro.ai/company/STE. Not investment advice — review the underlying SEC filings before making any trade.

Where does 13F Pro source STE data?

All STERIS plc fundamentals and ownership data come directly from SEC EDGAR. STERIS plc files with the SEC under CIK 1757898. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

STERIS plc STE

NYSELarge CapHealthcare

InternationalScored off the official board: an annual-only filer, so this data lags a domestic quarterly filer.

13F Pro quality score

Rank #328 of 2,925TOP 25%

Why it scores 68 Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed. Next update: ~Nov 14, 2026.

Revenue

$1.49B

Quarter to Jun 30

Net income

$200.10M

Quarter to Jun 30

Free cash flow

$279.60M

Quarter to Jun 30

Operating margin

19.1%

Quarter to Jun 30

Top Institutional Holders

as of Q2 2026

$20.00B total

BlackRock, Inc.

$1.86B-2.3%

VANGUARD CAPITAL MANAGEMENT LLC

$1.35B+0.6%

STATE STREET CORP

$1.07B+1.6%

VANGUARD PORTFOLIO MANAGEMENT LLC

$1.05B+1.0%

MASSACHUSETTS FINANCIAL SERVICES CO /MA/

$850.36M-5.2%

MORGAN STANLEY

$831.77M-10.1%

WELLINGTON MANAGEMENT GROUP LLP

$737.61M+21.9%

Orbis Allan Gray Ltd

$563.85M+3.3%

GEODE CAPITAL MANAGEMENT, LLC

$548.62M+1.3%

GENERATION INVESTMENT MANAGEMENT LLP

$480.25M-1.2%

Mitsubishi UFJ Asset Management Co., Ltd.

$463.30M+0.2%

Select Equity Group, L.P.

$398.96M-11.6%

Jupiter Topco LLC

$397.52M--

PRICE T ROWE ASSOCIATES INC /MD/

$386.24M+4.0%

Invesco Ltd.

$380.33M+5.7%

Boston Partners

$315.50M+73.8%

GOLDMAN SACHS GROUP INC

$287.04M+257.2%

AQR CAPITAL MANAGEMENT LLC

$285.84M+29.8%

ARROWSTREET CAPITAL, LIMITED PARTNERSHIP

$256.45M+134.4%

DIMENSIONAL FUND ADVISORS LP

$252.64M+7.7%

NORGES BANK

$251.04M--

BESSEMER GROUP INC

$219.61M-0.5%

NORTHERN TRUST CORP

$194.91M+1.9%

PRINCIPAL FINANCIAL GROUP INC

$188.59M+0.6%

BANK OF AMERICA CORP /DE/

$175.85M-9.4%

See all 842 institutional holders →

What's Driving STE's Business? Latest 10-Q Breakdown

AI-extracted from the 10-Q filed 2026-08-07 — Q1 FY2027 (quarter ended June 30, 2026). Every figure is machine-verified against the filing text on SEC EDGAR.

Biggest Revenue Drivers

Healthcare segment$1,048.3M+7.6% YoY

Growth in service (+9.6%), consumable (+9.2%), and capital equipment (+1.4%) driven by increased volume and pricing.

Applied Sterilization Technologies (AST)$297.6M+5.8% YoY

Constant currency organic growth of 4.7% primarily from increased pricing, partially offset by volume decline.

Biggest Revenue Drivers

Total revenue: $1,492.7M+7.3% YoY

Healthcare segment$1,048.3M+7.6% YoY

Growth in service (+9.6%), consumable (+9.2%), and capital equipment (+1.4%) driven by increased volume and pricing.

Applied Sterilization Technologies (AST)$297.6M+5.8% YoY

Constant currency organic growth of 4.7% primarily from increased pricing, partially offset by volume decline.

Life Sciences segment$146.7M+8.6% YoY

Growth in capital equipment (+17.4%), consumable (+8.2%), and service (+2.4%) driven by increased volume and pricing.

Largest Expense Items

Cost of revenues$808.6M+5.9% YoY

Increase driven by higher volume and inflation, partially offset by favorable pricing and productivity.

Selling, general, and administrative$369.7M+4.5% YoY

Increase attributable to higher compensation and benefit costs and marketing/sales spending, offset by favorable FX and lower bad debt.

Research and development$28.6M+8.5% YoY

Continued investment focused on sterile processing, procedural products, and gastrointestinal endoscopy device capabilities.

Margins: Gross profit margin expanded 70 basis points to 45.8%, driven by favorable pricing (100 bps), productivity (40 bps), and mix (40 bps), partially offset by inflation (60 bps) and adjustments (50 bps). Operating margin improved on higher volumes and operational efficiency.

Watch Items from the Filing

New restructuring plan announced post-quarter (Aug 5, 2026) expects $55M–$70M in total charges, with completion targeted in FY2030, impacting Chemistry manufacturing consolidation.
IRS dispute regarding deemed dividend inclusions and withholding tax for FY2018; potential liability of $50M (excluding interest/penalties); case pending in U.S. Tax Court.
Illinois EO litigation settlement obligations of $48.2M accrued in FY2025; substantially all payments made by July 31, 2026, with claims administration largely completed.
AST segment operating margin declined 60 bps to 48.0% due to higher depreciation, lower productivity, and labor inflation outweighing pricing gains.

AI-extracted and verified against SEC EDGAR filing text. Not investment advice.

Read the full 10-Q on SEC EDGAR →

Key Metrics

Revenue

Q1 2027

EDGAR

Net Income

Q1 2027

EDGAR

EPS (Diluted)

Q1 2027

EDGAR

Operating Margin

Q1 2027

EDGAR

ROIC

Q1 2027

EDGAR

Free Cash Flow

Q1 2027

EDGAR

Debt/Equity

Q1 2027

EDGAR

Financial Trends

Revenue & Net Income

13fpro.ai/company/STE

Earnings Per Share

13fpro.ai/company/STE

Loading ratio trend…

STERIS plc reported revenue, net income and margins by fiscal period, from SEC filings.
Period	Form	Revenue	Net income	Op. marginOperating margin
FY 2026	10-K	$5.9B	$782.3M	18.6%
FY 2025	10-K	$5.5B	$614.6M	15.9%
FY 2024	10-K	$5.1B	$378.2M	16.3%
FY 2023	10-K	$4.5B	$107.0M	17.4%
FY 2022	10-K	$4.2B	$243.9M	11.3%
FY 2021	10-K	$3.1B	$397.4M	17.6%

About STERIS plc (STE): stock profile, AI score and financials

STERIS plc (STE) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. 13F Pro's AI-powered ranking engine scores STE at 68.0/100 on a composite quality score built from its SEC filings, placing it at rank #328 of 2,925 stocks — the top 25% of the AI-ranked universe. Based on the latest XBRL financial filings (Q1 2027), STERIS plc reports quarterly revenue of $1.5B, net income of $200.1M, an operating margin of 19.1%. Top institutional holders of STE by reported 13-F value include BlackRock, VANGUARD CAPITAL MANAGEMENT, STATE STREET, based on the most recent SEC filings. STE trades on the NYSE exchange and files with the SEC under CIK 1757898. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate STE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for STERIS plc directly from SEC EDGAR.

Financials through the period ended Jun 30, 2026SEC EDGAR: CIK 1757898 →

STERIS plc STE

Top Institutional Holders

What's Driving STE's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Biggest Revenue Drivers

Largest Expense Items

Watch Items from the Filing

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

STE key financials by period

STE insiders

Congress trading in STE

About STERIS plc (STE): stock profile, AI score and financials

STERIS plc STE

Top Institutional Holders

What's Driving STE's Business? Latest 10-Q Breakdown

Biggest Revenue Drivers

Key Metrics

Financial Trends

Revenue & Net Income

Earnings Per Share

STE key financials by period

Companies similar to STE

STE insiders

Congress trading in STE

About STERIS plc (STE): stock profile, AI score and financials